Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.69 |
| ▸ | PI4KA | P42356 | 3/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.69 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | AHCY | P23526 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15841807 | 0.86 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL11222112 | 0.85 | ADORA2A (0.80) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12925855 | 0.83 | ADORA2A (0.71) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5065704 | 0.82 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1871838 | 0.81 | ADORA2A (0.75) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22558037 | 0.81 | ADORA2A (0.69) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1924594 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1798270 | 0.81 | ADORA2A (0.72) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16057701 | 0.80 | ADORA2A (0.68) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2638103 | 0.80 | ADORA2A (0.73) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102812013-B | Novel benzopyran kinase modulators | RHIZEN PHARMACEUTICALS S.A. (CH) | 2016-05-25 | — | — | CN | claimed |
| CN-103702989-A | Novel compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA | 2014-04-02 | — | — | CN | claimed |
| CN-100509833-C | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2009-07-08 | — | — | CN | claimed |
| CN-1630661-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2005-06-22 | — | — | CN | claimed |
| US-20040220120-A1 | Novel anhydrolide derivatives having antibacterial activity | VO NHA HUU (US) | 2004-11-04 | — | — | US | claimed |
| WO-2004069854-A1 | NOVEL ANHYDROLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS. INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-6720308-B1 | Anhydrolide derivatives having antibacterial activity | ENANTA PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | claimed |
| CN-116854772-A | Analogue of endomorphin and adenine conjugated peptide with analgesic activity and synthesis method thereof | 中国人民解放军空军军医大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-102812013-B | Novel benzopyran kinase modulators | RHIZEN PHARMACEUTICALS S.A. (CH) | 2016-05-25 | — | — | CN | disclosed |
| CN-103702989-A | Novel compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA | 2014-04-02 | — | — | CN | disclosed |
| CN-101115764-B | New macrolides | BASILEA PHARMACEUTICA AG | 2012-09-26 | — | — | CN | disclosed |
| CN-101289483-B | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG | 2012-06-20 | — | — | CN | disclosed |
| EP-1888615-B1 | 17 -HSD1 AND STS INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20060281710-A1 | 17SS-HSD1 and STS inhibitors | SOLVAY PHARMACEUTICALS GMBH | 2006-12-14 | — | — | US | disclosed |
| CN-1234718-C | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-01-04 | — | — | CN | disclosed |
| CN-1630661-A | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2005-06-22 | — | — | CN | disclosed |
| US-20040220120-A1 | Novel anhydrolide derivatives having antibacterial activity | VO NHA HUU (US) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069854-A1 | NOVEL ANHYDROLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS. INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-6720308-B1 | Anhydrolide derivatives having antibacterial activity | ENANTA PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| CN-1464880-A | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-12-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281710-A1 | 17SS-HSD1 and STS inhibitors | HSD17B11, HSD17B1, STS | ADORA2A 4764/4885ADORA1 4129/4885PI4KA 3292/4885 |
| US-20040220120-A1 | Novel anhydrolide derivatives having antibacterial activity | GALE, GNE, GMDS | ADORA2A 2432/4885ADORA1 1463/4885PI4KA 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.